JP2018035162A5 - - Google Patents

Download PDF

Info

Publication number
JP2018035162A5
JP2018035162A5 JP2017172825A JP2017172825A JP2018035162A5 JP 2018035162 A5 JP2018035162 A5 JP 2018035162A5 JP 2017172825 A JP2017172825 A JP 2017172825A JP 2017172825 A JP2017172825 A JP 2017172825A JP 2018035162 A5 JP2018035162 A5 JP 2018035162A5
Authority
JP
Japan
Prior art keywords
therapeutic agent
superoxide dismutase
agent according
administered
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017172825A
Other languages
English (en)
Japanese (ja)
Other versions
JP6382416B2 (ja
JP2018035162A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2018035162A publication Critical patent/JP2018035162A/ja
Publication of JP2018035162A5 publication Critical patent/JP2018035162A5/ja
Application granted granted Critical
Publication of JP6382416B2 publication Critical patent/JP6382416B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017172825A 2011-09-26 2017-09-08 疾患の治療方法 Active JP6382416B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161539365P 2011-09-26 2011-09-26
US61/539,365 2011-09-26

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014532075A Division JP6267638B2 (ja) 2011-09-26 2012-09-24 疾患の治療方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018145207A Division JP6736618B2 (ja) 2011-09-26 2018-08-01 疾患の治療方法

Publications (3)

Publication Number Publication Date
JP2018035162A JP2018035162A (ja) 2018-03-08
JP2018035162A5 true JP2018035162A5 (OSRAM) 2018-08-02
JP6382416B2 JP6382416B2 (ja) 2018-08-29

Family

ID=47911939

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2014532075A Active JP6267638B2 (ja) 2011-09-26 2012-09-24 疾患の治療方法
JP2017172825A Active JP6382416B2 (ja) 2011-09-26 2017-09-08 疾患の治療方法
JP2018145207A Active JP6736618B2 (ja) 2011-09-26 2018-08-01 疾患の治療方法
JP2020121417A Active JP7562125B2 (ja) 2011-09-26 2020-07-15 疾患の治療方法
JP2022200192A Active JP7697688B2 (ja) 2011-09-26 2022-12-15 疾患の治療方法
JP2025094341A Pending JP2025131753A (ja) 2011-09-26 2025-06-05 疾患の治療方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2014532075A Active JP6267638B2 (ja) 2011-09-26 2012-09-24 疾患の治療方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2018145207A Active JP6736618B2 (ja) 2011-09-26 2018-08-01 疾患の治療方法
JP2020121417A Active JP7562125B2 (ja) 2011-09-26 2020-07-15 疾患の治療方法
JP2022200192A Active JP7697688B2 (ja) 2011-09-26 2022-12-15 疾患の治療方法
JP2025094341A Pending JP2025131753A (ja) 2011-09-26 2025-06-05 疾患の治療方法

Country Status (8)

Country Link
US (5) US9149483B2 (OSRAM)
EP (1) EP2760874A4 (OSRAM)
JP (6) JP6267638B2 (OSRAM)
CN (2) CN111467351A (OSRAM)
AU (5) AU2012316397B2 (OSRAM)
CA (2) CA3120505C (OSRAM)
HK (1) HK1199261A1 (OSRAM)
WO (1) WO2013048965A1 (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2056675T3 (en) 2006-10-12 2019-04-23 Galera Labs Llc Methods for treating oral mucositis
CA3120505C (en) 2011-09-26 2024-11-12 Galera Labs, Llc METHODS OF TREATING DISEASES
TWI746449B (zh) * 2015-07-20 2021-11-21 美商Ａｉ治療公司 使用阿吡莫德治療癌症之方法
WO2017027728A1 (en) * 2015-08-11 2017-02-16 Galera Labs, Llc Pentaaza macrocyclic ring complexes possessing oral bioavailability
CN109414454A (zh) * 2016-05-03 2019-03-01 加莱拉实验室有限责任公司 用于癌症治疗的组合疗法
US11219614B2 (en) 2016-09-01 2022-01-11 Galera Labs, Llc Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound
CN110520107A (zh) * 2017-02-15 2019-11-29 加莱拉实验室有限责任公司 用于局部肠递送的五氮杂大环状环配合物
US11246950B2 (en) 2017-04-13 2022-02-15 Galera Labs, Llc Combination cancer immunotherapy with pentaaza macrocyclic ring complex
WO2019152661A1 (en) * 2018-01-31 2019-08-08 Galera Labs, Llc Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent
JP7770026B2 (ja) * 2019-10-10 2025-11-14 ガレラ・ラブス・リミテッド・ライアビリティ・カンパニー マンガン含有配位錯体の水性製剤の製造方法、製剤および処置方法
EP4103573A1 (en) * 2020-02-13 2022-12-21 Teva Pharmaceuticals International GmbH Solid state forms of avasopasem manganese and process for preparation thereof

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001212A (en) 1973-10-03 1977-01-04 E. I. Du Pont De Nemours And Company Macrocyclic polyamines
US3930867A (en) 1974-01-07 1976-01-06 E. I. Du Pont De Nemours And Company Macrocyclic polyamines as sensitizers for silver halide emulsions
JPS61226751A (ja) 1985-03-30 1986-10-08 Konishiroku Photo Ind Co Ltd ハロゲン化銀写真感光材料用処理液及びその処理方法
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5096724A (en) 1988-06-03 1992-03-17 Aquanautics Corporation Methods, compositions, and systems for ligand extraction
GB9001245D0 (en) 1990-01-19 1990-03-21 Salutar Inc Compounds
CA2072934C (en) 1991-07-19 2007-08-28 Karl William Aston Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
EP0524161A1 (en) 1991-07-19 1993-01-20 Monsanto Company Manganese complexes of nitrogen containing macrocyclic ligands effective as catalysts for dismutating superoxide
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US6204259B1 (en) 1993-01-14 2001-03-20 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
PL316968A1 (en) 1994-04-22 1997-03-03 Monsanto Co Method of analysing diagnostic images employing the metal complexes with nitrogen containing macrocyclic ligands
US6245758B1 (en) 1994-05-13 2001-06-12 Michael K. Stern Methods of use for peroxynitrite decomposition catalysts, pharmaceutical compositions therefor
JPH0840941A (ja) 1994-07-29 1996-02-13 Kanegafuchi Chem Ind Co Ltd 炎症性腸疾患治療製剤
US6525041B1 (en) 1995-06-06 2003-02-25 Pharmacia Corporation Manganese or iron complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
WO1997006830A1 (en) 1995-08-17 1997-02-27 Monsanto Company Methods of diagnostic image analysis using bioconjugates of metal complexes of nitrogen-containing macrocyclic ligands
JP2000513322A (ja) * 1995-08-17 2000-10-10 モンサント カンパニー スーパーオキシドをジスムテートする触媒として有効な窒素含有大環状リガンドのマンガン錯体の生体分子結合体
AU6722496A (en) 1995-08-17 1997-03-12 Monsanto Company Methods of diagnostic image analysis using metal complexes of nitrogen-containing macrocyclic ligands
US20050171198A1 (en) 1997-06-20 2005-08-04 Metaphore Pharmaceuticals, Inc. SODm therapy for treatment, prevention, inhibition and reversal of inflammatory disease
US20060270639A1 (en) 1997-06-20 2006-11-30 Daniela Salvemini Combinations of superoxide dismutase mimetics and nonsteroidal analgesic/anti-inflammatory drugs
US6214817B1 (en) * 1997-06-20 2001-04-10 Monsanto Company Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity
US6180620B1 (en) 1997-06-20 2001-01-30 G.D. Searle & Co. Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals
US20020128248A1 (en) 1997-06-20 2002-09-12 Metaphore Pharmaceuticals, Inc SODm therapy for prevention and/or treatment of inflammatory disease
JP2991172B2 (ja) 1997-10-24 1999-12-20 日本電気株式会社 半導体装置
IL135949A0 (en) 1997-11-03 2001-05-20 Univ Duke Substituted porphyrins
GB9817845D0 (en) 1998-08-17 1998-10-14 Glaxo Group Ltd Chemical compounds
US6040330A (en) * 1999-01-08 2000-03-21 Bionumerik Pharmaceuticals, Inc. Pharmaceutical formulations of taxanes
JP2003500174A (ja) 1999-05-27 2003-01-07 フアルマシア・コーポレーシヨン スーパーオキシド・ジスムターゼ模倣体で修飾された生体材料
US6448239B1 (en) 1999-06-03 2002-09-10 Trustees Of Princeton University Peroxynitrite decomposition catalysts and methods of use thereof
AU761674B2 (en) 1999-06-23 2003-06-05 Eric F. Bernstein Use of nitroxides in wound healing and in the prevention of photodamage
CA2399293C (en) 2000-02-08 2012-01-03 Rice University Optically-active nanoparticles for use in therapeutic and diagnostic methods
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
EP1315481B1 (de) 2000-08-29 2006-12-06 Mepha AG Arzneimittel zur behandlung von darmerkrankungen
US6589948B1 (en) * 2000-11-28 2003-07-08 Eukarion, Inc. Cyclic salen-metal compounds: reactive oxygen species scavengers useful as antioxidants in the treatment and prevention of diseases
US7166910B2 (en) 2000-11-28 2007-01-23 Knowles Electronics Llc Miniature silicon condenser microphone
US20020072512A1 (en) 2000-12-08 2002-06-13 Metaphore Pharmaceuticals, Inc Method of preventing and treating HIV-mediated central nervous system damage
WO2002053142A2 (en) 2001-01-05 2002-07-11 Metaphore Pharmaceuticals, Inc. Compositions and methods for enhancing cytokine activity and treating hypotension associated with the administration of cytokines
DK1392328T3 (da) 2001-01-19 2009-11-09 Nat Jewish Health Medikament til beskyttelse i radioterapi
WO2002058686A2 (en) 2001-01-26 2002-08-01 Metaphore Pharmaceuticals, Inc. Method of treatment of neurodegenerative disorders using pentaaza-macrocyclic ligand complexes
US20040137638A1 (en) 2002-03-04 2004-07-15 Slomczynska Urszula J. Chromatography of metal complexes
WO2002071054A1 (en) 2001-03-02 2002-09-12 Metaphore Pharmaceuticals, Inc. Chromatography of metal complexes
WO2002100395A1 (en) 2001-06-08 2002-12-19 Genzyme Corporation Bismuth salts of anti-oxidants and radical scavengers for prevention and treatment of mucous membrane ulcers
US20040132706A1 (en) 2001-10-05 2004-07-08 Daniela Salvemini Composition comprising a catalyst for the dismutation of superoxide and use of the composition for preventing and treating hypotension
RU2313368C2 (ru) 2001-11-01 2007-12-27 Ю Эй Би Рисерч Фаундейшн Комбинации антител, обладающих селективностью по отношению к рецептору лиганда, индуцирующему апоптоз, ассоциированный с фактором некроза опухоли, и других терапевтических средств
EP1463563B1 (en) * 2001-12-14 2009-02-18 Alcon, Inc. Superoxide dismutase mimics for the treatment of ocular disorders and diseases
EP1501526A1 (en) 2002-04-16 2005-02-02 Isis Innovation Limited Curcumin for the prevention and/or treatment of tissue damage
US20050101581A1 (en) 2002-08-28 2005-05-12 Reading Christopher L. Therapeutic treatment methods 2
US6781231B2 (en) 2002-09-10 2004-08-24 Knowles Electronics Llc Microelectromechanical system package with environmental and interference shield
US6798047B1 (en) 2002-12-26 2004-09-28 Amkor Technology, Inc. Pre-molded leadframe
WO2005042718A2 (en) 2003-10-31 2005-05-12 Metaphore Pharmaceuticals, Inc. Compositions and methods for treating, preventing, reversing and inhibiting pain
FR2863892B1 (fr) 2003-12-18 2007-05-11 Univ Paris Descartes Utilisation de mimetiques de la superoxyde dismutase et de la glutathion reductase comme anti-cancereux
US7510710B2 (en) 2004-01-08 2009-03-31 The Regents Of The University Of Colorado Compositions of UCP inhibitors, Fas antibody, a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor
US7432369B2 (en) 2004-03-29 2008-10-07 Inotek Pharmaceuticals Corporation Pyridyl-substituted porphyrin compounds and methods of use thereof
US7262498B2 (en) 2004-10-19 2007-08-28 Hewlett-Packard Development Company, L.P. Assembly with a ring and bonding pads formed of a same material on a substrate
US20070148154A1 (en) 2004-12-17 2007-06-28 Universite Rene Descartes (Paris V) Use of superoxide dismutase mimetics and reductase gultatione in the form of anticancer drugs
US8217166B2 (en) 2005-05-05 2012-07-10 Galera Therapeutics, Llc Polyethylene glycolated superoxide dismutase mimetics
WO2006083508A2 (en) 2005-01-10 2006-08-10 Metaphore Pharmaceuticals Inc. Combinations of superoxide dismutase mimetics and nonsteroidal analgesic/anti-inflammatory drugs
WO2006078713A2 (en) 2005-01-19 2006-07-27 Metaphore Pharmaceuticals, Inc. Methotrexate combinations for treating inflammatory diseases
EP1863778B1 (en) 2005-03-31 2015-12-30 Merck Sharp & Dohme Corp. Spirocyclic thrombin receptor antagonists
CN2870352Y (zh) 2005-12-23 2007-02-14 瑞声声学科技(深圳)有限公司 微机电系统传声器扣合式封装结构
WO2007139897A1 (en) 2006-05-23 2007-12-06 University Of Utah Research Foundation Compositions and methods for the inhibition of endothelial nitric oxide synthase activity
US20080139525A1 (en) 2006-08-31 2008-06-12 The Brigham And Women's Hospital, Inc. Antioxidant therapies
US20080161324A1 (en) 2006-09-14 2008-07-03 Johansen Lisa M Compositions and methods for treatment of viral diseases
DK2056675T3 (en) 2006-10-12 2019-04-23 Galera Labs Llc Methods for treating oral mucositis
TWI333264B (en) 2007-01-10 2010-11-11 Advanced Semiconductor Eng Packaging structure and method of mems microphone
RU2010114059A (ru) * 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) Применение фибронектинового фрагмента (196-203) в качестве терапевтического средства
MX2010009453A (es) 2008-02-29 2011-03-01 Eagle Pharmaceuticals Inc Soluciones de topotecano listas para utilizarse.
US20090257979A1 (en) 2008-04-15 2009-10-15 Intermune, Inc. Novel Inhibitors of Hepatitis C Virus Replication
ES2530462T3 (es) * 2008-05-22 2015-03-03 Galera Therapeutics Llc Combinación terapia antitumoral
EP2545073B1 (en) 2010-03-12 2015-09-30 AbbVie Biotherapeutics Inc. Ctla4 proteins and their uses
US20120207687A1 (en) 2011-01-14 2012-08-16 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Topical formulations of targeted nitroxide agents
CA3120505C (en) * 2011-09-26 2024-11-12 Galera Labs, Llc METHODS OF TREATING DISEASES
US9238659B2 (en) 2012-11-19 2016-01-19 The University Of Hong Kong Method of using binuclear gold (I) compounds for cancer treatment
WO2017027728A1 (en) 2015-08-11 2017-02-16 Galera Labs, Llc Pentaaza macrocyclic ring complexes possessing oral bioavailability
CN109414454A (zh) 2016-05-03 2019-03-01 加莱拉实验室有限责任公司 用于癌症治疗的组合疗法
US11219614B2 (en) 2016-09-01 2022-01-11 Galera Labs, Llc Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound
WO2018125862A1 (en) 2016-12-27 2018-07-05 Soon Kap Hahn Prevention of local tumor recurrence following surgery using sustained and/or delayed release of medicaments contained in micro-particles
CN110520107A (zh) 2017-02-15 2019-11-29 加莱拉实验室有限责任公司 用于局部肠递送的五氮杂大环状环配合物
EP3388082A1 (en) 2017-04-13 2018-10-17 Galera Labs, LLC Combination cancer immunotherapy with pentaaza macrocyclic ring complex
KR20190141690A (ko) 2017-04-13 2019-12-24 갈레라 랩스, 엘엘씨 펜타아자 마크로시클릭 고리 복합체를 사용한 조합 암 면역요법
US11246950B2 (en) 2017-04-13 2022-02-15 Galera Labs, Llc Combination cancer immunotherapy with pentaaza macrocyclic ring complex
WO2019152661A1 (en) 2018-01-31 2019-08-08 Galera Labs, Llc Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent

Similar Documents

Publication Publication Date Title
JP2018035162A5 (OSRAM)
JP2018184465A5 (OSRAM)
Rejhová et al. Natural compounds and combination therapy in colorectal cancer treatment
JP2020183416A5 (OSRAM)
JP2014526562A5 (OSRAM)
CN105452258B (zh) 使用双核金(i)化合物用于癌症治疗的方法
JP2015524444A5 (OSRAM)
JP2013067645A5 (OSRAM)
JP2011503111A5 (ja) ４−ヨード−３−ニトロベンズアミド化合物と抗腫瘍剤の組み合わせによる乳がんの治療
JP2015523397A5 (OSRAM)
JP2018533589A5 (OSRAM)
JP2020523356A5 (OSRAM)
JP2019508476A5 (OSRAM)
JP2013518124A5 (OSRAM)
JP2017537124A5 (OSRAM)
JP2014508758A5 (OSRAM)
JP2014512355A5 (OSRAM)
TW201141472A (en) Method to treat small cell lung cancer
JP2019513706A5 (OSRAM)
Karpuz et al. Clinical applications of nanosized drug-delivery systems in lung cancer imaging and therapy
RU2015139515A (ru) Комбинированное лечение
JP2025015727A (ja) ｐ－ボロノフェニルアラニンを含有する注射液剤
JP2018516964A (ja) 局所進行性または転移性である肝内もしくは肝外胆管または胆嚢のカルシノーマに罹患する患者を治療する方法
KR20210130768A (ko) 경구 투여된 디옥솔란 뉴클레오타이드와 항-pd1 또는 항-pdl1 단일클론 항체를 함께 사용하여 간암을 치료하는 방법
RU2678103C2 (ru) Противоопухолевое средство, содержащее противоопухолевый комплекс платины, и усилитель противоопухолевого эффекта